174 institutions hold shares in TCR2 Therapeutics Inc. (TCRR), with 527.44k shares held by insiders accounting for 1.38% while institutional investors hold 98.03% of the company’s shares. The shares outstanding are 33.49M, and float is at 25.71M with Short Float at 12.81%. Institutions hold 96.67% of the Float.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
The top institutional shareholder in the company is MPM Asset Management, LLC with over 4.05 million shares valued at $125.29 million. The investor’s holdings represent 10.62% of the TCRR Shares outstanding. As of Dec 30, 2020, the second largest holder is Wellington Management Group, LLP with 3.75 million shares valued at $116.09 million to account for 9.84% of the shares outstanding. The other top investors are MPM ONCOLOGY IMPACT MANAGEMENT LP which holds 3.37 million shares representing 8.84% and valued at over $104.26 million, while Redmile Group, LLC holds 7.43% of the shares totaling 2.83 million with a market value of $87.62 million.
TCR2 Therapeutics Inc. (NASDAQ: TCRR) is -27.90% lower on its value in year-to-date trading and has touched a low of $7.19 and a high of $35.86 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The TCRR stock was last observed hovering at around $23.40 in the last trading session, with the day’s loss setting it -1.1% off its average median price target of $42.00 for the next 12 months. It is also 60.88% off the consensus price target high of $57.00 offered by 9 analysts, but current levels are 34.41% higher than the price target low of $34.00 for the same period.
Currently trading at $22.30, the stock is -7.08% and -14.21% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.51 million and changing -4.70% at the moment leaves the stock -2.94% off its SMA200. TCRR registered 218.12% gain for a year compared to 6-month gain of 10.51%. The firm has a 50-day simple moving average (SMA 50) of $25.33 and a 200-day simple moving average (SMA200) of $25.76.
The stock witnessed a -10.08% loss in the last 1 month and extending the period to 3 months gives it a -25.91%, and is 4.16% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 6.83% over the week and 7.97% over the month.
Distance from 52-week low is 210.04% and -37.81% from its 52-week high.
TCR2 Therapeutics Inc. (TCRR) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for TCR2 Therapeutics Inc. (TCRR) is a “Buy”. 9 analysts offering their recommendations for the stock have an average rating of 1.70, where 0 rate it as a Hold and 0 think it is a “Overweight”. 9 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
TCR2 Therapeutics Inc. is expected to release its quarterly report on 08/12/2021 and quarterly earnings per share for the current quarter are estimated at -$0.52.The EPS is expected to grow by 48.10% this year
TCR2 Therapeutics Inc. (TCRR) Insider Activity
A total of 15 insider transactions have happened at TCR2 Therapeutics Inc. (TCRR) in the last six months, with sales accounting for 6 and purchases happening 9 times. The most recent transaction is an insider sale by Somaiya Mayur Ian, the company’s Chief Financial Officer. SEC filings show that Somaiya Mayur Ian sold 2,000 shares of the company’s common stock on Dec 14 at a price of $35.00 per share for a total of $70000.0. Following the sale, the insider now owns 1473.0 shares.
TCR2 Therapeutics Inc. disclosed in a document filed with the SEC on Nov 17 that Somaiya Mayur Ian (Chief Financial Officer) sold a total of 3,666 shares of the company’s common stock. The trade occurred on Nov 17 and was made at $30.00 per share for $0.11 million. Following the transaction, the insider now directly holds 1473.0 shares of the TCRR stock.
Still, SEC filings show that on Nov 12, Hofmeister Robert (Chief Scientific Officer) disposed off 20,000 shares at an average price of $25.10 for $0.5 million. The insider now directly holds 38,850 shares of TCR2 Therapeutics Inc. (TCRR).